Dr. Melanie Cree of Children’s Hospital Colorado helped rename polycystic ovary syndrome (PCOS) to poly-endocrine metabolic syndrome (PMOS) this month.
The name change seeks to shift the medical focus from the ovaries to the broader hormonal and metabolic systems. This transition is intended to reduce diagnostic confusion and improve the quality of care for patients who suffer from this multisystem disease.
Dr. Cree also founded a clinic for PMOS patients at Children’s Hospital Colorado in Denver. The new facility aims to provide integrated care that addresses the complex nature of the syndrome beyond reproductive health.
The condition affects between 10% and 13% of women worldwide [1]. Because the disorder impacts millions of women globally [2], advocates said that the previous name was an inaccurate description of the condition's pathology.
The shift to PMOS reflects a response to patient demand for a name that accurately describes their experience. By emphasizing the endocrine and metabolic components, the new terminology aligns the name with the actual biological drivers of the disorder.
Medical professionals said that the previous name focused too heavily on the presence of cysts on the ovaries. However, many patients with the syndrome do not have cysts, while others with cysts do not have the metabolic dysfunction associated with the disorder. The updated name removes this discrepancy, allowing for a more inclusive diagnostic framework.
“The name change seeks to shift the medical focus from the ovaries to the broader hormonal and metabolic systems.”
The transition from PCOS to PMOS represents a paradigm shift in how medical providers perceive and treat the disorder. By reclassifying it as a metabolic and endocrine syndrome rather than a primary ovarian issue, the medical community may reduce the underdiagnosis of patients who do not present with ovarian cysts but suffer from the condition's systemic metabolic effects.
